REG - Genedrive PLC - Scotland national roll-out of MT-RNR1 ID Kit

GenedriveAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251126:nRSZ9866Ia&default-theme=true

RNS Number : 9866I  Genedrive PLC  26 November 2025

genedrive plc

("genedrive" or the "Company")

 

Scotland national roll-out of Genedrive® MT-RNR1 ID Kit

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company,
is pleased to note the recent media coverage of its Genedrive® MT-RNR1 ID
Kit, which reduces the risk of deafness in newborn babies and introduced
initially by NHS Greater Glasgow and Clyde ("NHSGGC").

 

The Genedrive® MT-RNR1 ID Kit will start being used for babies requiring
antibiotic treatment for infections within the Neonatal Intensive Care Unit at
the Royal Hospital for Children ("RHC") in Glasgow, with the Royal Alexandra
Hospital and Princess Royal Maternity Hospital to follow soon after, as part
of a phased rollout to all NHS Scotland Health Boards with neonatal units over
the coming months.

 

Further details are available at:

 

https://news.stv.tv/scotland/groundbreaking-genetic-test-could-prevent-hearing-loss-in-babies
(https://news.stv.tv/scotland/groundbreaking-genetic-test-could-prevent-hearing-loss-in-babies)

 

https://www.nhscfsd.co.uk/news/new-genetic-test-aims-to-prevent-hearing-loss-for-babies-in-scotland/
(https://www.nhscfsd.co.uk/news/new-genetic-test-aims-to-prevent-hearing-loss-for-babies-in-scotland/)

 

Dr Gino Miele, CEO of genedrive plc, said: "We are proud that NHS Scotland has
begun to implement our interventional rapid genetic test nationally, ensuring
over time that it is available to neonates across Scotland who might otherwise
be at risk of hearing loss. As outlined in the STV news article above, the
potential impact on patients and family's lives is substantial and we look
forward to progressing coverage to all NHS Scotland Health boards".

 

Scottish Health Secretary, Neil Gray, said: "This test will have a
life-changing impact on newborn babies in Scotland as we roll it out across
the country through our Accelerated National Innovation Adoption pathway,
resulting in improved health outcomes and a better quality of life.  This
exceptional programme demonstrates the transformative potential of scientific
and technological innovation, and our commitment to delivering the ambitions
set out in our Programme for Government and the NHS Scotland Operational
Improvement Plan."

 

Dr Helen McDevitt, Consultant Neonatologist with NHSGGC, said: "National roll
out of this innovative point of care genetic test will prevent deafness in a
significant number of susceptible newborn infants each year in Scotland.
Patient care will be improved immeasurably by enhancing the safety of current
antibiotic treatments.  It's exciting that Scotland is at the forefront of
developing precision medicine from birth onwards."

 

Ryan Coppoer, Point of Care Testing Lead in National Services Scotland, said:
"This simple and gentle test gives us the ability to protect babies from
avoidable harm and hearing loss right from the very start of their lives.
This aims to not only safeguard their quality of life but give their families
and loved one's peace of mind.  By identifying those at risk within minutes
of birth, we can make safer treatment choices and give every child the best
chance to grow, learn and thrive without the challenges that hearing loss can
bring."

 

For further details please contact:

 

 genedrive plc                                     +44 (0)161 989 0245
 Gino Miele: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Broker)      +44 (0)20 7418 8900
 James Steel

 Walbrook PR Ltd (Media & Investor Relations)      +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                   (mailto:genedrive@walbrookpr.com)
 Anna Dunphy                                       +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedrive.com (http://www.genedrive.com) )

 

genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile and simple to use point of need
pharmacogenetic platform for the diagnosis of genetic variants. This helps
clinicians to quickly access key genetic information that will aid them make
the right choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care healthcare
paradigms. Based in the UK, the Company is at the forefront of Point of Care
pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on
how your individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be personalised,
made safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit,
both developed and validated in collaboration with NHS partners and deployed
on its point of care thermocycler platform. Both tests are single-use
disposable cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the Genedrive®
MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on
antibiotic use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially otherwise
encountered and with no negative impact on the patient care pathway. Its
CYP2C19 ID Kit which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke patients in
70 minutes, ensuring that patients who are unlikely to benefit from or suffer
adverse effects from Clopidogrel receive an alternative antiplatelet
therapeutic in a timely manner, ultimately improving outcomes. Both tests have
undergone review by the National Institute for Health and Care Clinical
Excellence ("NICE") and have been recommended for use in the UK NHS. The
Company has a clear commercial strategy focused on accelerating growth through
maximising in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in Manchester.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZMZMRKKGKZM



            Copyright 2019 Regulatory News Service, all rights reserved